When the National Institute of Mental Health published the results of the CATIE trial (Clinical Antipsychotic Trials of Intervention Effectiveness) in 2005, the surprise wasn't that newer atypical antipsychotics worked. It was that perphenazine — an older, cheaper, mid-potency typical antipsychotic from the 1950s — performed comparably to most of them on the trial's main outcome (time to discontinuation for any reason). For a generation of clinicians who had assumed atypicals were uniformly better, it was a useful corrective.
Perphenazine is a mid-potency phenothiazine antipsychotic that balances effectiveness, cost, and side effect burden — and which the CATIE trial showed to be a reasonable comparator to newer drugs.
What perphenazine is
Perphenazine — sold historically as Trilafon in the US, now mostly as a generic — is a phenothiazine antipsychotic. Its potency sits between the very-low-potency chlorpromazine and the very-high-potency fluphenazine. That middle position translates into a balanced side effect profile: less sedation and weight gain than chlorpromazine, less acute EPS than haloperidol or fluphenazine.
How it works
Perphenazine blocks dopamine D2 receptors, which is the main driver of its antipsychotic effect. It also has moderate activity at histamine, alpha-adrenergic, and serotonergic receptors, which explains its modest sedation and orthostatic effects. Compared with high-potency typicals it produces less acute EPS at standard doses, though the long-term tardive dyskinesia risk is similar across the typical class.
What it treats
Perphenazine is FDA-approved for:
- Schizophrenia
- Severe nausea and vomiting in adults
Forms and dosing
Perphenazine is available as oral tablets and oral concentrate. Daily doses for chronic schizophrenia are individualised between you and your prescriber. There is no widely available perphenazine depot in the US.
The CATIE trial in detail
The CATIE trial, summarised by NIMH on its research website, randomised more than 1,400 patients with chronic schizophrenia to one of five medications: perphenazine, olanzapine, quetiapine, risperidone, or ziprasidone. The primary outcome was time to discontinuation for any reason — a real-world measure that captures both efficacy and tolerability.
The headline findings:
- Olanzapine had the longest time to discontinuation, but produced the most weight gain and metabolic side effects
- Perphenazine performed comparably to risperidone, quetiapine, and ziprasidone
- EPS rates with perphenazine were not significantly higher than with the atypicals (though patients with prior tardive dyskinesia were excluded)
- Perphenazine cost a small fraction of the newer drugs
The trial complicated the simple story that atypicals were uniformly superior. It also rehabilitated the place of mid-potency typicals in modern practice.
Side effects
Movement
EPS occurs but tends to be milder than with haloperidol or fluphenazine at comparable D2 blockade. Akathisia is still common. Tardive dyskinesia risk with long-term use is similar to other typicals — see our guide on tardive dyskinesia.
Other
- Sedation (mild to moderate)
- Orthostatic hypotension (less than chlorpromazine, more than haloperidol)
- Hyperprolactinaemia
- Anticholinergic effects (dry mouth, constipation, blurry vision)
- QT prolongation
- Photosensitivity
High fever, severe muscle rigidity, confusion, and unstable vital signs (NMS); sudden painful muscle spasms (acute dystonia); fainting or new chest pain.
Where perphenazine fits
- Adults with schizophrenia where cost is a serious factor
- Patients who have done well on it historically
- Patients who tolerate typical antipsychotics in general but had problems with high-potency drugs
- Settings where atypicals are unavailable
Where it may not fit
- First-episode patients in well-resourced settings (where atypicals remain first-line)
- People with prior tardive dyskinesia
- Older adults with dementia (FDA boxed warning, like all antipsychotics)
The wider lesson
The most useful thing CATIE did was remind clinicians that "newer" doesn't automatically mean "better." Each medication choice is a balance: efficacy, side effect burden, cost, and the individual person's history with the drug class. Perphenazine remains, decades after its introduction, a rational choice for the right patient — and the data behind it are stronger than its quiet reputation suggests.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.